Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

765 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
[Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study].
Szucs TD, Guggenberger G, Berger K, März W, Schäfer JR. Szucs TD, et al. Among authors: marz w. Herz. 1998 Aug;23(5):319-29. doi: 10.1007/BF03044365. Herz. 1998. PMID: 9757381 Clinical Trial. German.
[Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial].
Szucs TD, Berger K, März W, Schäfer JR. Szucs TD, et al. Among authors: marz w. Herz. 2000 Aug;25(5):487-94. doi: 10.1007/pl00001961. Herz. 2000. PMID: 10992997 German.
Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns.
Ruof J, Klein G, März W, Wollschläger H, Neiss A, Wehling M. Ruof J, et al. Among authors: marz w. Prev Med. 2002 Jul;35(1):48-53. doi: 10.1006/pmed.2002.1050. Prev Med. 2002. PMID: 12079440 Clinical Trial.
[Guidelines for lowering lipids are too infrequently observed. Results of a retrospective study of coronary heart disease patients].
Klein G, Ruof J, März W, Wollschläger H, Neiss A, Wehling M. Klein G, et al. Among authors: marz w. MMW Fortschr Med. 2000 Aug 31;142(35):35-7. MMW Fortschr Med. 2000. PMID: 11006705 German.
HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
März W, Wieland H. März W, et al. Herz. 2000 Mar;25(2):117-25. doi: 10.1007/pl00001949. Herz. 2000. PMID: 10829251 Review.
[Clinical importance of HDL cholesterol].
März W, Kleber ME, Scharnagl H, Speer T, Zewinger S, Ritsch A, Parhofer KG, von Eckardstein A, Landmesser U, Laufs U. März W, et al. Herz. 2017 Feb;42(1):58-66. doi: 10.1007/s00059-016-4499-0. Epub 2016 Nov 14. Herz. 2017. PMID: 27844137 Review. German.
[Management of different cardiovascular risk factors with a combination tablet (polypill)].
Bramlage P, März W, Westermann D, Weisser B, Wirtz JH, Zeymer U, Baumgart P, van Mark G, Laufs U, Krämer BK, Unger T. Bramlage P, et al. Among authors: marz w. Herz. 2018 May;43(3):246-257. doi: 10.1007/s00059-017-4554-5. Epub 2017 Mar 24. Herz. 2018. PMID: 28341983 Review. German.
Determination of pravastatin by high performance liquid chromatography.
Siekmeier R, Gross W, März W. Siekmeier R, et al. Among authors: marz w. Int J Clin Pharmacol Ther. 2000 Sep;38(9):419-25. doi: 10.5414/cpp38419. Int J Clin Pharmacol Ther. 2000. PMID: 11020028
Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
März W, Dippel FW, Theobald K, Gorcyca K, Iorga ŞR, Ansell D. März W, et al. Atherosclerosis. 2018 Jan;268:99-107. doi: 10.1016/j.atherosclerosis.2017.11.020. Epub 2017 Nov 20. Atherosclerosis. 2018. PMID: 29197254
[Consequences of the "A to Z" studies: Cholesterol in acute coronary syndrome early and aggressive reduction?].
März W. März W. Herz. 2005 Feb;30(1):78-80. Herz. 2005. PMID: 16167397 German. No abstract available.
765 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback